- Home
- TWIN vs CHRS Comparison
TWIN vs CHRS Comparison
Compare TWIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- CHRS
- Stock Information
- Founded
- TWIN 1918
- CHRS 2010
- Country
- TWIN United States
- CHRS United States
- Employees
- TWIN N/A
- CHRS N/A
- Industry
- TWIN Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWIN Industrials
- CHRS Health Care
- Exchange
- TWIN Nasdaq
- CHRS Nasdaq
- Market Cap
- TWIN 97.0M
- CHRS 84.2M
- IPO Year
- TWIN N/A
- CHRS 2014
- Fundamental
- Price
- TWIN $8.73
- CHRS $0.73
- Analyst Decision
- TWIN Strong Buy
- CHRS Buy
- Analyst Count
- TWIN 1
- CHRS 3
- Target Price
- TWIN $12.00
- CHRS $4.68
- AVG Volume (30 Days)
- TWIN 154.6K
- CHRS 1.3M
- Earning Date
- TWIN 08-14-2025
- CHRS 08-07-2025
- Dividend Yield
- TWIN 1.82%
- CHRS N/A
- EPS Growth
- TWIN N/A
- CHRS N/A
- EPS
- TWIN 0.29
- CHRS N/A
- Revenue
- TWIN $328,478,000.00
- CHRS $272,251,000.00
- Revenue This Year
- TWIN $27.91
- CHRS N/A
- Revenue Next Year
- TWIN N/A
- CHRS $106.56
- P/E Ratio
- TWIN $30.14
- CHRS N/A
- Revenue Growth
- TWIN 11.49
- CHRS 19.87
- 52 Week Low
- TWIN $6.16
- CHRS $0.66
- 52 Week High
- TWIN $14.98
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- TWIN 70.14
- CHRS 41.45
- Support Level
- TWIN $7.43
- CHRS $0.72
- Resistance Level
- TWIN $9.05
- CHRS $0.77
- Average True Range (ATR)
- TWIN 0.38
- CHRS 0.04
- MACD
- TWIN 0.13
- CHRS 0.00
- Stochastic Oscillator
- TWIN 84.97
- CHRS 13.65
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.